Diving briefs:
- A group of shareholders has filed a lawsuit against UnitedHealth, claiming the company misled them about the impact of the death of Brian Thompson, CEO of its insurance division, on its corporate strategies regarding healthcare denial.
- The lawsuit, submitted on Wednesday in Manhattan Federal Court, seeks class action status, arguing that shareholders faced negative consequences due to this alleged deception.
- The plaintiffs are seeking damages from UnitedHealth for individuals who purchased shares between December 2024 and April 2025. UnitedHealth has expressed its intention to fight the lawsuit.
Dive Insights:
Thompson’s murder in early December occurred during a stay at a Manhattan hotel for UnitedHealth’s Annual Investor Day. His death has startled the public and intensified discussions about insurers profiting from the denial or postponement of healthcare, an issue that seems to be fueling crime.
As the leading private insurer in the U.S., serving over 50 million members, UnitedHealthcare is currently under scrutiny from lawmakers and regulators, particularly regarding its care denial rates, which are reportedly higher than those of many competitors.
The lawsuit asserts there is no substantiated damage to shareholders from UnitedHealth’s actions. It claims that the financial guidance issued for 2025, announced prior to Thompson’s death, quickly became misleading amid the resulting confusion, yet the company reiterated it earlier this year.
According to the lawsuit, the statements made were misleading because they did not reflect the company’s shift away from ambitious goals due to growing hostility from consumers, which may enable undue denial tactics aiming to achieve profits of $28.15-$28.65. The lawsuit describes this as a reckless maneuver by the company.
A clearer understanding of UnitedHealth’s financial state emerged in April when it released its first-quarter results for 2025.
The company also cut its profit forecast for the year by 12%, attributing it to unexpectedly high care costs for Medicare Advantage participants. Analysts noted that this might lead to a reduction in management processes like prior authorization, possibly resulting in more approvals for medical care.
Following Thompson’s death, UnitedHealth committed to easing restrictions that might limit treatment approvals.
Since the financial results were shared, UnitedHealth’s stock has plummeted 33%, wiping out over $150 billion in market value. The stock price is currently at its lowest since mid-2021.
UnitedHealth’s value has dropped significantly over the past six months
Prices for $unh will end by December 2024
The lawsuit claims that the defendant’s actions and omissions have led to a sharp decline in the company’s market value, causing significant losses for shareholders and other class members.
The plaintiff’s attorneys believe there could be hundreds or even thousands of individuals eligible for “substantial damages” as part of the proposed class.
In a statement, a spokesperson for UnitedHealth affirmed that the company will deny any claims of fraud and will vigorously contest the lawsuit.
Previously, shareholders attempted to hold the company accountable, and a group of faith-based investors proposed investigating the implications of care denial on business and patients. However, this proposal was retracted last month after UnitedHealth intervened.
